Cantor Fitzgerald restates Bicara Therapeutics stock rating
Corroborated by 2 sources from 2 publishers
TL;DR
During the quarter, consumer spending bucked broader macroeconomic worries amid heightened tensions in the Middle East, while payment volume increased Cantor Fitzgerald reiterates Rocket Lab stock Overweight rating at $96.
Sources
1
Yahoo Finance News
https://finance.yahoo.com/markets/stocks/articles/cantor-fitzgerald-reaffirms-overweight-rating-102758540.html
2
Investing.com News
https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-rocket-lab-stock-overweight-rating-at-96-93CH-4712083
3
Investing.com News
https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-cuts-zscaler-stock-price-target-on-capex-concerns-93CH-4712144
4
Investing.com News
https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-raises-defi-development-stock-price-target-to-7-on-treasury-yield-expansion-93CH-4712143
5
Investing.com News
https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-bicara-therapeutics-stock-rating-93CH-4712163